PD-L1的表达与妇科恶性肿瘤预后关系的研究进展

doi:10.11904/j.issn.1002-3070.2018.05.017

摘要/Abstract

摘要： 程序性死亡蛋白1(Programmed death protein 1,PD-1)是T细胞上主要存在的一种抑制性受体。程序性死亡配体-1(Programmed death ligand-1,PD-L1,又称B7-H1)在心、肝、肾、肺等多个器官上皮细胞和内皮细胞中广泛表达。肿瘤发生时机体内的肿瘤微环境会使浸润性T细胞高表达PD-1,同时肿瘤细胞中PD-L1的表达上调,与PD-1受体相结合,导致肿瘤微环境中PD-1通路持续开放,进而导致T细胞凋亡,肿瘤细胞则逃脱机体的免疫监视,发生肿瘤免疫逃逸。本文就PD-L1表达与妇科恶性肿瘤预后关系的研究进展进行综述。

关键词: 程序性死亡配体-1, 程序性死亡蛋白1, 妇科恶性肿瘤, 预后

Abstract: Programmed death protein 1(PD-1)is a major inhibitory receptor in T cells.Programmed death ligand-1(PD-L1,also known as B7-H1)is widely expressed in epithelial cells and endothelial cells of many organs such as heart,liver,kidney and lung.Tumor microenvironment in tumorigenesis causes invasive T cells to express PD-1,and PD-L1 is up-regulated in tumor cells,which binds to the PD-1 receptor,resulting in sustained PD-1 pathway in tumor microenvironment,inducing T cell apoptosis and escaping the immune surveillance to cause tumor immune escape.This article reviews the research progress of the relationship between the expression of PD-L and the prognosis of gynecologic malignancies.

Key words: Programmed death ligand-1, Programmed death protein 1, Gynecological malignancy, Prognosis

中图分类号:

R737.3

韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.

HAN Teng, TANG Liping. Advances in the relationship between the PD-L1 expression and the prognosis of gynecologic malignancies[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 468-470.

参考文献

1 Freeman GJ,Long AJ,Iwai Y,et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J].J Exp Med,2000,192(7):1027-1034.
2 Velcheti V,Schalper KA,Carvajal DE,et al.Programmed death ligand-1 expression in non-small cell lung cancer[J].Lab Invest,2014,94(1):107-116.
3 Shi F,Shi M,Zeng Z,et al.PD-1 and PD-L1 upregulation promotes CD8(+)T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients[J].Int J Cancer,2011,128(4):887-896.
4 Ghebeh H,Mohammed S,Al-Omair A,et al.The B7-H1(PDL1)T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma:correlation with important high-risk prognostic factors[J].Neoplasia,2006,8(3):190-198.
5 Keir ME,Butte MJ,Freeman GJ,et al.PD-1 and its ligands in tolerance and immunity[J].Annu Rev Immunol,2008,26:677-704.
6 Hanna GJ,Woo SB,Li YY,et al.Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma[J].Int J Oral Maxillofac Surg,2017,29(9):55-62.
7 Zhou C,Tang J,Sun H,et al.PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer[J].Oncotarget,2017,8(35):58457-58468.
8 贺红英,曾定元,林佳静,等.154 例宫颈低分化鳞癌预后影响因素及治疗方式的探讨[J].中国妇幼保健,2014,29(6):837-840.
9 郑晓霞,李琼珍,李玲,等.宫颈癌预后状况及其影响因素分析[J].实用癌症杂志,2014,29(3):314-316.
10 Heeren AM,Punt S,Bleeker MC,et al.Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix[J].Mod Pathol,2016,29(7):753-763.
11 Zhang Y,Zhu W,Zhang X,et al.Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer[J].Oncol Lett,2017,14(6):7225-7231.
12 Siegel R,Naishadham D,Jemal A.Cancer statistics,2012[J].CA Cancer Clin,2012,62(1):10-29.
13 Wang Q,Lou W,Di W,et al.Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer[J].Int Immunopharmacol,2017,52:7-14.
14 Zhu J,Wen H,Bi R,et al.Prognostic value of programmed death-ligand 1(PD-L1)expression in ovarian clear cell carcinoma.[J].Gynecol Oncol,2017,28(6):e77.
15 Tan D,Sheng L,Yi QH.Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer[J].Cancer Biomark,2018,21(2):287-297.
16 Eggink FA,Van Gool IC,Leary A,et al.Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition[J].Oncoimmunology,2017,6(2):621-627.
17 Yamashita H,Nakayama K,Ishikawa M,et al.Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer[J].Oncotarget,2018,9(5):5652-5664.
18 Morice P,Leary A,Creutzberg C,et al.Endometrial cancer[J].Lancet,2016,387(10023):1094-1108.
19 Herbst RS,Baas P,Kim DW,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer(KEYNOTE-010):a randomised controlled trial[J].Lancet,2016,387(10027):1540-1550.
20 Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
21 Clancy AA,Spaans JN,Weberpals JI.The forgotten woman′s cancer:vulvar squamous cell carcinoma(VSCC)and a targeted approach to therapy[J].Ann Oncol,2016,27(9):1696-1705.
22 Sznurkowski JJ,Z·awrocki A,Sznurkowska K,et al.PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients[J].Oncotarget,2017,8(52):89903-89912.
23 Hecking T,Thiesler T,Schiller C,et al.Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology[J].Oncotarget,2017,8(54):92890-92903.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[4]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[5]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[6]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[7]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[8]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[9]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[10]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[11]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[12]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[13]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[14]	李美艳, 陈永学, 侯俊德. Leptin、VEGF及不同麻醉方式对子宫内膜癌患者预后生存的影响[J]. 实用肿瘤学杂志, 2018, 32(5): 426-431.
[15]	杜灵彬, 魏文强. 中国人群食管鳞癌生存分析研究新进展[J]. 实用肿瘤学杂志, 2018, 32(4): 344-348.